Table of Contents
✨ Onyx Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in three upcoming investor events - Citi’s 2025 Biopharma Back to School Summit, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference - where management will engage in one-on-one meetings with investors.
The company continues to advance its Gene Traffic Control® platform and oncology pipeline, reinforcing its visibility within the biopharma investment community as it develops therapies targeting chromatin regulatory dependencies.
CAMBRIDGE, Mass., Aug. 27, 2025 – August 27, 2025 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi’s 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control ® platform and resulting broad pipeline have the potential to transform the lives of people suffering
from a wide spectrum of diseases.
Citi’s 2025 Biopharma Back to School Summit
Date: Wednesday, September 3, 2025
Management will participate in one-on-one meetings
2025 Wells Fargo Healthcare Conference
Date: Thursday, September 4, 2025
Management will participate in one-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Monday, September 8, 2025
Management will participate in one-on-one meetings
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
